Introduction:

Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) are neurosteroids. They are involved in many different neurological pathways that promote the generation and survival of neurons (Maninger et al., 2010). These neuroprotective effects make DHEA and DHEA-S the research focus on treatments for a number of neurological and neuropsychiatric diseases, including depression, schizophrenia, and dementia. DHEA has been extensively studied and is demonstrated to be useful for depression (Peixoto et al., 2014), while some studies also provided evidence for the efficacy of DHEA for schizophrenia (Strous et al., 2003) and dementia (Wolkowitz et al., 2003). With these emerging evidence, DHEA may be a useful brain supplement to improve brain health and functions.

Future Research

• DHEA/S ratio to other hormones as biomarkers for neurological/neuropsychiatric diseases

• Assess the efficacy and establish guidelines for DHEA monotherapy or adjunctive therapy for neurological/neuropsychiatric diseases

• Larger, longer clinical studies on dementia, schizophrenia, etc.

References

Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Synthia, H. (2010). Neurobiological and Neuropsychiatric Effects of DHEA and DHEA-s. NIH Public Access, 30(1), 65–91. https://doi.org/10.1016/j.yfrne.2008.11.002.Neurobiological

Peixoto, C., Devicari Cheda, J., Nardi, A., Veras, A., & Cardoso, A. (2014). The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review. Current Drug Targets, 15(9), 901–914. https://doi.org/10.2174/1389450115666140717111116

Strous, R. D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., & Weizman, A. (2003). Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia. Archives of General Psychiatry, 60(2), 133. https://doi.org/10.1001/archpsyc.60.2.133

Wolkowitz, O. M., Kramer, J. H., Reus, V. I., Costa, M. M., Yaffe, K., Walton, P., Raskind, M., Peskind, E., Newhouse, P., Sack, D., De Souza, E., Sadowsky, C., & Roberts, E. (2003). DHEA treatment of Alzheimer’s disease: A randomized, double-blind, placebo-controlled study. Neurology, 60(7), 1071–1076. https://doi.org/10.1212/01.WNL.0000052994.54660.58 

Schverer, M., Lanfumey, L., Baulieu, E. E., Froger, N., & Villey, I. (2018). Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases. Pharmacology and Therapeutics, 191, 190–206. https://doi.org/10.1016/j.pharmthera.2018.06.011

Stárka, L., Dušková, M., & Hill, M. (2015). Dehydroepiandrosterone: A neuroactive steroid. Journal of Steroid Biochemistry and Molecular Biology, 145, 254–260. https://doi.org/10.1016/j.jsbmb.2014.03.008  

Maggio, M., De Vita, F., Fisichella, A., Colizzi, E., Provenzano, S., Lauretani, F., Luci, M., Ceresini, G., Dall’Aglio, E., Caffarra, P., Valenti, G., & Ceda, G. P. (2015). DHEA and cognitive function in the elderly. The Journal of Steroid Biochemistry and Molecular Biology, 145, 281–292. https://doi.org/10.1016/j.jsbmb.2014.03.014

Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Synthia, H. (2010). Neurobiological and Neuropsychiatric Effects of DHEA and DHEA-s. NIH Public Access, 30(1), 65–91. https://doi.org/10.1016/j.yfrne.2008.11.002.Neurobiological

Kessler, R. C. (2012). The costs of depression. Psychiatric Clinics, 35(1), 1-14.

Barnes, T. R., Leeson, V. C., Mutsatsa, S. H., Watt, H. C., Hutton, S. B., & Joyce, E. M. (2008). Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. The British journal of psychiatry, 193(3), 203-209.

Castro, D. M., Dillon, C., Machnicki, G., & Allegri, R. F. (2010). The economic cost of Alzheimer's disease: Family or public-health burden?. Dementia & Neuropsychologia, 4(4), 262-267.

Schizophrenia - Symptoms and causes - Mayo Clinic. (n.d.). Retrieved August 23, 2020, from https://www.mayoclinic.org/diseases-conditions/schizophrenia/symptoms-causes/syc-20354443

The Cost of Dementia Care in 2018. (n.d.). Retrieved August 23, 2020, from https://www.alzheimers.net/the-cost-of-dementia-care  

Fishback, J. A., Robson, M. J., Xu, Y.-T., & Matsumoto, R. R. (2010). Sigma receptors: Potential targets for a new class of antidepressant drug. Pharmacology & Therapeutics, 127(3), 271–282. https://doi.org/10.1016/j.pharmthera.2010.04.003

Kubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., & Maes, M. (2011). In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(3), 744–759. https://doi.org/10.1016/j.pnpbp.2010.08.026

Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011). A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(3), 676–692. https://doi.org/10.1016/j.pnpbp.2010.05.004

Steckler, T., Holsboer, F., & Reul, J. M. H. M. (1999). Glucocorticoids and depression. Best Practice & Research Clinical Endocrinology & Metabolism, 13(4), 597–614. https://doi.org/10.1053/beem.1999.0046

Briley, M., & Chantal, M. (2011). The importance of norepinephrine in depression. Neuropsychiatric Disease and Treatment, 9. https://doi.org/10.2147/NDT.S19619

Dunlop, B. W., & Nemeroff, C. B. (2007). The Role of Dopamine in the Pathophysiology of Depression. Archives of General Psychiatry, 64(3), 327. https://doi.org/10.1001/archpsyc.64.3.327

Peixoto, C., Devicari Cheda, J., Nardi, A., Veras, A., & Cardoso, A. (2014). The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review. Current Drug Targets, 15(9), 901–914. https://doi.org/10.2174/1389450115666140717111116

Balu, D. T. (2016). The NMDA Receptor and Schizophrenia (pp. 351–382). https://doi.org/10.1016/bs.apha.2016.01.006

Abi-Dargham, A., & Moore, H. (2003). Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia. The Neuroscientist, 9(5), 404–416. https://doi.org/10.1177/1073858403252674

Misiak, B., Frydecka, D., Loska, O., Moustafa, A. A., Samochowiec, J., Kasznia, J., & Stańczykiewicz, B. (2018). Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis. Psychoneuroendocrinology, 89, 92–102. https://doi.org/10.1016/j.psyneuen.2018.01.007

Gallagher, P., Watson, S., Smith, M., Young, A., & Ferrier, I. (2007). Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophrenia Research, 90(1–3), 258–265. https://doi.org/10.1016/j.schres.2006.11.020

Harris, D. S., Wolkowitz, O. M., & Reus, V. I. (2001). Movement Disorder, Memory, Psychiatric Symptoms and Serum DHEA Levels in Schizophrenic and Schizoaffective Patients. The World Journal of Biological Psychiatry, 2(2), 99–102. https://doi.org/10.3109/15622970109027500

Ritsner, M., Gibel, A., Ram, E., Maayan, R., & Weizman, A. (2006). Alterations in DHEA metabolism in schizophrenia: Two-month case-control study. European Neuropsychopharmacology, 16(2), 137–146. 

Strous, R. D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., & Weizman, A. (2003). Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia. Archives of General Psychiatry, 60(2), 133. https://doi.org/10.1001/archpsyc.60.2.133

Quinn, T. A., Robinson, S. R., & Walker, D. (2018). Dehydroepiandrosterone (DHEA) and DHEA Sulfate: Roles in Brain Function and Disease. In Sex Hormones in Neurodegenerative Processes and Diseases. InTech. https://doi.org/10.5772/intechopen.71141

Chen, L., Dai, X.-N., & Sokabe, M. (2006). Chronic administration of dehydroepiandrosterone sulfate (DHEAS) primes for facilitated induction of long-term potentiation via sigma 1 (σ1) receptor: Optical imaging study in rat hippocampal slices. Neuropharmacology, 50(3), 380–392. https://doi.org/10.1016/j.neuropharm.2005.10.015

Bastianetto, S., Ramassamy, C., Poirier, J., & Quirion, R. (1999). Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Molecular Brain Research, 66(1–2), 35–41. https://doi.org/10.1016/S0169-328X(99)00002-9

Tamagno, E., Guglielmotto, M., Bardini, P., Santoro, G., Davit, A., Di Simone, D., Danni, O., & Tabaton, M. (2003). Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiology of Disease, 14(2), 291–301. https://doi.org/10.1016/S0969-9961(03)00131-1

Wolkowitz, O. M., Kramer, J. H., Reus, V. I., Costa, M. M., Yaffe, K., Walton, P., Raskind, M., Peskind, E., Newhouse, P., Sack, D., De Souza, E., Sadowsky, C., & Roberts, E. (2003). DHEA treatment of Alzheimer’s disease: A randomized, double-blind, placebo-controlled study. Neurology, 60(7), 1071–1076. https://doi.org/10.1212/01.WNL.0000052994.54660.58